All In Biotech

Drug Trial Radar · NCT06777264

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1

Clinical Study on Inaticabtagene Autoleucel (Inati-cel; CNCT19) Injection for Adolescents and Adults With B-Cell Acute Lymphoblastic Leukemia in First Complete Remission (CR1)

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jan 15, 2025

Primary completion

Dec 15, 2026

Study completion Jan 15, 2027

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This investigator-initiated, prospective, single-arm, open-label, single-center phase II study aims to evaluate the long-term survival benefit and safety of a commercial CD19 CAR-T product in newly diagnosed Philadelphia chromosome-positive or negative (Ph-positive or Ph-negative) B-cell ALL patients who achieve CR1 after induction chemotherapy. A total of 20 patients will be enrolled in the study. The primary endpoints include disease-free survival (DFS) and overall survival (OS) rates after a median follow-up of 2 years, minimal residual disease (MRD) negativity rate, and the proportion of patients undergoing subsequent hematopoietic stem cell transplantation (HSCT). The frequency and severity of adverse events (AEs) and serious adverse events (SAEs) occurring after infusion will also be recorded.

Conditions

  • Acute Lymphoblastic Leukemia
  • B Cell ALL

Interventions

  • Biological: single dose of Inaticabtagene autoleucelBiological

    Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 2-year DFS rate (2yDFSR)Time frame: Up to 2 years
  2. 2-year OS rate (2yDFSR)Time frame: Up to 2 years
  3. DFSTime frame: Up to 2 years
  4. OSTime frame: Till the end of the study, up to 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.